Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics ...

CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control. CellPryme-A acts ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX: PTX) CEO James McDonnell discusses the company’s ...

Ras proteins were originally identified as oncogenes able to induce cell transformation. Since then they have been shown to regulate distinct signaling pathways and induce the proliferation ...

Appendix cancer is a rare but increasingly recognized malignancy, often discovered incidentally during surgery for presumed ...